US Federal 2025-2026 Regular Session

US Federal House Bill HB5917

Introduced
 
Introduced
11/4/25  

Caption

To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries.

Summary

HB5917 would give the President authority to end the application of Title IV of the Trade Act of 1974 to a covered country and then extend nondiscriminatory treatment, also known as normal trade relations (NTR), to that country’s products. In practical terms, the bill creates a mechanism for removing certain trade restrictions and moving a country into a more standard trade status, subject to presidential determination. The bill applies broadly to countries except Belarus, Cuba, and North Korea, which are explicitly excluded from the definition of a covered country. The bill’s core effect is to amend how the Trade Act of 1974 applies to foreign countries by allowing the President to terminate Title IV coverage and proclaim NTR treatment for imports from eligible countries. Once that determination is made and the extension takes effect, Title IV would no longer apply to that country. The measure would therefore affect U.S. trade policy, import treatment, and the legal status of products from countries that could be moved out of restrictive trade provisions.

Impact

HB5917 would alter the operation of Title IV of the Trade Act of 1974 by giving the President discretion to discontinue its application to a covered country and extend normal trade relations treatment to that country’s products. This would affect tariff and trade-status rules for imports from eligible countries, while preserving the exclusion of Belarus, Cuba, and North Korea. The bill does not itself name specific countries to be covered; instead, it establishes a legal pathway for future presidential action affecting trade relations and import treatment.

Sentiment

Available context shows little recorded debate or voting activity, so there is no documented controversy or support-opposition split in the materials provided. The bill’s introduction by Representatives Miller and Panetta suggests bipartisan sponsorship, which may indicate an intent to provide the executive branch with flexibility in trade policy. Because the bill was only referred to the House Committee on Ways and Means and no votes or transcripts are available, the overall sentiment cannot be measured beyond the bill’s straightforward, procedural trade-policy framing.

Contention

The main point of potential contention is the breadth of presidential discretion: the bill would let the President decide when Title IV should no longer apply to a covered country and when to extend normal trade relations treatment. Supporters may view this as a flexible tool for updating trade relationships, while critics could see it as reducing congressional control over trade policy or weakening leverage over foreign governments. Another likely issue is which countries could benefit, since the bill excludes only Belarus, Cuba, and North Korea and otherwise leaves the category of covered countries broad.

Companion Bills

US SB3103

Same As A bill to authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries.

Previously Filed As

US SB3103

A bill to authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries.

US HB2329

Uzbekistan Normalized Trade Act

US HB377

Authorizes an individual to refuse certain medical treatments

US HB1024

US-Kazakhstan Trade Modernization Act

US HB1504

China Trade Relations Act of 2025

US HB7521

United States-Cuba Trade Act of 2026

US HB7091

Expanding Veterans’ Access to Emerging Treatments Act

US HB3799

Relating to medical treatments with investigational products.

US SB3081

Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

US HB1632

Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

Similar Bills

No similar bills found.